Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Nordic Nanovector ASA ( (DE:8NN) ) is now available.
Thor Medical ASA has successfully completed an oversubscribed subsequent offering of 4,000,000 new shares, raising NOK 10 million in gross proceeds. The share capital increase is expected to be registered shortly, with shares being delivered to subscribers by mid-July 2025, enhancing the company’s financial position and potentially strengthening its market presence.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier in the radiopharmaceutical industry, specializing in the production of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. The company is known for its proprietary production process that does not require irradiation or nuclear reactors, offering a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters. Thor Medical is based in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
Average Trading Volume: 2,172,363
Current Market Cap: NOK782.9M
For detailed information about 8NN stock, go to TipRanks’ Stock Analysis page.